The Federal Commission for the Protection of Health Risks (Cofepris) issued two health alerts on 15 October for the counterfeiting and marketing of vaccines to immunize influenza.
In the first alert, Cofepris reports that it was notified by Sanofi Pasteur of the counterfeiting and marketing of the product Fluzone Quadrivalent f.f suspension, with health registration number 146M2014 and identified with the batch numbers: EUH2174AC, EUH071AB and E0H071AB, all with expiration date of January 22.
Read: Patient tested positive for COVID and influenza, first case in Mexico
Sanofi Pasteur, points out the alert of Cofepris has stated that the batches indicated have not been manufactured or distributed by the company and does not recognize as its own the EUH2174AC, EUH071AB and E0H071AB lots of the Fluzone Quadrivalent product, so its sale is irregular.
This product is an inactivated tetravalent vaccine for immunization against the disease caused by influenza type A viruses (H1N1 and H3N2) and subtypes B contained in the vaccine.
Currently this vaccine is in the process of being analyzed by Cofepris for sale and distribution in the Mexican market, so Sanofi Pasteur has not distributed any batch of the product for commercialization in national territory.
The second alert is for the illegal marketing of the product Vaxigrip f.f suspension, with health registration number 478M96 SSA, produced, also by Sanofi Pasteur, for exclusive use of the health sector, with the batch numbers: U3J091V and U3J481V, both with an expiry date of June 21.
Find out: AMLO says COVID will be vaccinated as soon as vaccines arrive to give citizens confidence
This is a vaccine for active immunization against influenza A and B viruses.
The company Sanofi Pasteur informed COFEPRIS that it received reports on the marketing and application in hospitals, offices and private coexistence centers, vaxigrip f.f suspension, with batch numbers U3J09 and U3J48.
As reported by the company, this product is for the exclusive use of the health sector, so it should not be marketed or applied in hospitals, offices, pharmacies or any other private establishment, since its safety and efficacy are not guaranteed.
Cofepris recommends that private hospitals, pharmacies and outlets, refrain from purchasing to market products for the exclusive use of the health sector and if the Fluzone Quadrivalent product is found, identified with the EUH2174AC, EUH071AB and E0H071AB lots among their inventories, they must freeze it and give notice to the Federal Commission.
The general population is advised not to purchase any of the products reported in the alerts and, if identified, perform
a health complaint on the following website: https://www.gob.mx/cofepris/acciones-y-programas/denuncias-sanitarias
It is also recommended that the population report any adverse reactions or discomfort related to the use or consumption of medicines on the Cofepris website or via mail [email protected]
What we do at Animal Politics requires professional journalists, teamwork, dialogue with readers and something very important: independence. You can help us keep going. Be part of the team.
Subscribe to Animal Politics, receive benefits and support free journalism.#YoSoyAnimal
